Calistoga Pharmaceuticals calistogapharma.com


Public list: Pharma Startups (4732) Cancer Therapeutics (1137)

Calistoga Pharmaceuticals is a biopharmaceutical company developing multiple compounds selectively targeting the PI3K pathway, a pathway known to be involved in certain cancers and inflammatory diseases. In February 2011, Calistoga Pharmaceuticals was acquired by Gilead Sciences. The valuation of Calistoga Pharmaceuticals was $375 million.

Calistoga Pharmaceuticals is a biopharmaceutical company developing multiple compounds selectively targeting the PI3K pathway, a pathway known to be involved in certain cancers and inflammatory diseases. In February 2011, Calistoga Pharmaceuticals ...Show all

Company (Acquired)

Phone: 206-728-4700

Fax:

2101 - 4th Avenue
Suite 1960
Seattle, 98121
Washington, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Calistoga Pharmaceuticals $96.2M Feb 7, 2011
See all 16 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Calistoga Pharmaceuticals Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 6 investors

Board Members

Competitors

Company Status Description Investors

Syndax Pharmaceuticals

Waltham, Massachusetts, United States
IPO / Went publicSyndax is a clinical stage biopharmaceutical company developing entinostat as a combination therapy in multiple cancer indications with an initial focus on tumors that have shown sensitivity to immunotherapy, including lung cancer, melanoma and triple negative breast cancer. Entinostat is an oral, small molecule drug candidate that has direct effects on both cancer cells and immune regulatory cells, potentially enhancing the body's immune response to tumors. Entinostat is being evaluated in a Ph...Show allLogin to see details

Elixir Pharmaceuticals

Cambridge, Massachusetts, United States
Dead / InactiveElixir Pharmaceuticals a Cambridge MA-based biopharmaceutical company focuses on developing and commercializing drugs to treat and prevent metabolic disease and age-related diseases.Login to see details
See all 16 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)